Navigation Links
Zyomyx, Inc. Receives ISO 13485: 2003 Certification
Date:2/28/2013

FREMONT, Calif., Feb. 28, 2013 /PRNewswire/ -- Zyomyx, Inc., developer of the first quantitative disposable CD4 diagnostic, has achieved ISO 13485: 2003 certification for its quality management system. Certification was awarded by BSI, one of the world's leading certification bodies.

Achieving ISO 13485: 2003 certification is a critical first step toward both WHO Pre-Qualification and a CE mark. WHO Pre-Qualification requires a quality management system to ensure Good Manufacturing Practices (GMP) and is the regulatory clearance recognized by many policy makers, global health funding organizations, and governments of developing countries. A CE mark is the regulatory clearance requirement recognized in Europe and by many other countries and global health funding organizations. 

"ISO 13485 certification is a major corporate milestone for Zyomyx that moves us closer to the expected launch of our innovative CD4 point-of-care test this year," said Peter Wagner , CEO of Zyomyx, Inc. "This strengthens the confidence our customers and partners have in Zyomyx and provides a solid foundation as we adapt our novel platform technology for other clinical applications as a leader in the commercialization of highly accessible cell count diagnostics."

About ISO 13485: 2003

ISO 13485: 2003 is an international standard, globally recognized for establishing quality management systems that consistently meet customer and regulatory requirements for safe and effective medical devices. ISO 13485 is based on quality management principles that have been proven to enhance organization performance. These principles relate to customer focus, management, internal processes and external relationships.

About Zyomyx, Inc.

Zyomyx, Inc., a privately held diagnostics company based in Fremont, California, is an innovator in the development and commercialization of proprietary diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's immediate focus is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries.

For more information, visit http://www.zyomyx.com

Contact: Joanna Sickler , 510-265-8000, jsickler@zyomyx.com


'/>"/>
SOURCE Zyomyx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... ... 2018 , ... Researchers performing pressurized NMR or EPR experiments face a danger ... for High-Pressure NMR & EPR by Wilmad-LabGlass – SP Scienceware shields researchers from ... High-pressure experiments have significantly grown in popularity over the last several years. As a ...
(Date:8/9/2018)... ... August 08, 2018 , ... ActX introduces ... is continually updated by a talented scientific team that includes geneticists, PharmD’s, genetic ... , 1. Information on the medical impact of a patient’s genetic variants , ...
(Date:8/9/2018)... ... 08, 2018 , ... Since their establishment in 2012, ambitions have been high ... double its’ size from last year, the company is thrilled to announce the release ... impressed crowds at a private product launch event during the annual Protein Society Symposium ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland ... and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed ... was published online on August 9, 2018 and will be printed in the ...
Breaking Biology Technology:
(Date:8/2/2018)... AUSTIN, Texas (PRWEB) , ... August 02, 2018 ... ... Lance Anderson, member partner in our Austin office, has been named Practice Group ... , “I am honored to help continue growing Dickinson Wright’s healthcare and life ...
(Date:8/1/2018)... (PRWEB) , ... August 01, 2018 , ... ... portfolio, announces the release of Limfinity® version 7.1. Limfinity® is the software framework ... Limfinity® itself creates new possibilities for both current users and the future of ...
(Date:7/31/2018)... ... ... ACEA Biosciences, is a privately owned biotechnology company which develops cutting edge instrumentation ... which the ideal entry level model for exploratory studies in cell biology. ... standard CO2 tissue culture incubator. The user friendly RTCA software allows for real-time ...
Breaking Biology News(10 mins):